Peritumoral edema enhances MRI-based deep learning radiomic model for axillary lymph node metastasis burden prediction in breast cancer.

Journal: Scientific reports
PMID:

Abstract

To investigate whether peritumoral edema (PE) could enhance deep learning radiomic (DLR) model in predicting axillary lymph node metastasis (ALNM) burden in breast cancer. Invasive breast cancer patients with preoperative MRI were retrospectively enrolled and categorized into low (< 2 lymph nodes involved (LNs+)) and high (≥ 2 LNs+) burden groups based on surgical pathology. PE was evaluated on T2WI, and intra- and peri-tumoral radiomic features were extracted from MRI-visible tumors in DCE-MRI. Deep learning models were developed for LN burden prediction in the training cohort and validated in an independent cohort. The incremental value of PE was evaluated through receiver operating characteristic (ROC) analysis, confirming the improvement in the area under the curve (AUC) using the Delong test. This was complemented by net reclassification improvement (NRI) and integrated discrimination improvement (IDI) metrics. The deep learning combined model, incorporating PE with selected radiomic features, demonstrated significantly higher AUC values compared to the MRI model and the DLR model in the training cohort (n = 177) (AUC: 0.953 vs. 0.849 and 0.867, p < 0.05) and the validation cohort (n = 111) (AUC: 0.963 vs. 0.883 and 0.882, p < 0.05). The complementary analysis demonstrated that PE significantly enhances the prediction performance of the DLR model (Categorical NRI: 0.551, p < 0.001; IDI = 0.343, p < 0.001). These findings were confirmed in the validation cohort (Categorical NRI: 0.539, p < 0.001; IDI = 0.387, p < 0.001). PE improved preoperative ALNM burden prediction of DLR model, facilitating personalized axillary management in breast cancer patients.

Authors

  • Hongbing Luo
    Department of Radiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, 4th Section of South Ren-Min Road, Chengdu, 610041, China. rohbin@163.com.
  • Zhe Chen
    Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Hao Xu
    Department of Nuclear Medicine, the First Affiliated Hospital, Jinan University, Guangzhou 510632, P.R.China.gdhyx2012@126.com.
  • Jing Ren
    College of Life Science and Engineering, Lanzhou University of TechnologyLanzhou 730050, P. R. China; The Key Lab of Screening, Evaluation and Advanced Processing of TCM and Tibetan Medicine, Education Department of Gansu Provincial GovernmentLanzhou 730050, P. R. China.
  • Peng Zhou
    School of International Studies, Zhejiang University, Hangzhou, China.